Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azilsartan - Takeda

Drug Profile

Azilsartan - Takeda

Alternative Names: Azilva; TAK-536

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Lees Pharmaceutical Holdings; Takeda
  • Class Antihypertensives; Benzimidazoles; Oxadiazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Phase III Essential hypertension

Most Recent Events

  • 01 Aug 2018 Lee's Pharmaceutical completes a phase III trial in Essential hypertension (In adults, In the elderly) in China (PO) (NCT02609490)
  • 24 Jun 2018 Biomarkers information updated
  • 11 Mar 2018 Takeda completes a phase I trial in Essential hypertension (In volunteers, In adults) in Japan (PO) (NCT03434977)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top